Amgen’s Bkemv Earns FDA Approval as First Interchangeable Biosimilar to Soliris

The FDA approved Amgen’s Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to AstraZeneca’s Soliris (eculizumab) to treat the rare diseases paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
Source: Drug Industry Daily